Results 161 to 170 of about 1,782,146 (327)
Activation of Epstein-Barr Virus by 5-Bromodeoxyuridine in “Virus-Free” Human Cells
Paul J. Gerber
openalex +1 more source
Establishment of a lymphoblastoid cell line and isolation of an Epstein-Barr-related virus of gorilla origin [PDF]
Russell H. Neubauer+4 more
openalex +1 more source
The article describes the treatment of Epstein–Barr viral infection under the mask of the systemic variant of the juvenile rheumatoid arthritis. The clinical presentations of the disease included fever, rash, lymphadenopathy, hepatomegaly, polyarticular ...
T.M. Bzarova+2 more
doaj
Implications of Tobacco Use on Pathogen‐Driven Diseases: A Public Health and Policy Perspective
ABSTRACT The tobacco epidemic remains one of the most significant global public health challenges, responsible for over 8 million deaths annually, with a substantial portion occurring among non‐smokers exposed to second‐hand smoke. While cigarette smoking remains the most prevalent form of tobacco use worldwide, the rise of electronic nicotine delivery
Nadine Kabbani, James L. Olds
wiley +1 more source
A Longitudinal Comparison of Antibodies to Epstein-Barr Virus and Clinical Parameters in Chronic Lymphocytic Leukemia and Chronic Myelocytic Leukemia [PDF]
Paul H. Levine+5 more
openalex +1 more source
Detection of LMP1 protein in Breast Cancer tissue samples from Fars province hospitals
Background and Aim: Breast cancer is the most common malignancy among women and Epstein Barr virus could be a reason to develop this cancer. The aim of this study is to evaluate the association between Epstein Barr virus and breast cancer by ...
Afsoon Shariat
doaj
Gastrointestinal Barrier Disruption in Post‐COVID Syndrome Fatigue Patients
Gastrointestinal (GI) barrier disruption in the context of SARS‐CoV‐2 infection is associated with the development of Post‐COVID Syndrome (PCS) Fatigue. Pre‐existing GI complaints may predispose to fatigue development. Monitoring GI symptoms and markers before, during, and after SARS‐CoV‐2 infection is crucial for identifying predictive clinical ...
Johanna Rohrhofer+8 more
wiley +1 more source
A 6‐month randomized, double‐blind, placebo‐controlled first‐in‐human clinical trial was conducted in birch pollen allergic patients comparing the Bet v 1‐fold‐variant BM41 with a licensed birch pollen extract‐based treatment, as active comparator, and placebo.
Lorenz Aglas+17 more
wiley +1 more source